Elysium Basis combines nicotinamide riboside chloride with pterostilbene. It is an oral precursor product, and its published research needs to be separated into blood-NAD findings, safety observations, and exploratory symptom studies.
This is a review of public product information and original papers, not a firsthand product test. We have not independently assayed a pouch, verified an individual customer’s lot, or measured clinical outcomes.
Basis has identifiable ingredients and published studies. The biomarker evidence is more established than broad anti-aging or menopause-treatment claims.
What is the formulation being discussed?
The official product page identifies NR chloride and pterostilbene. Elysium’s study explanation describes the standard researched combination as 250 mg NR plus 50 mg pterostilbene. Pterostilbene is related to, but different from, resveratrol. Compare the current pouch label with the studied formulation, and do not assume that another Elysium product has the same evidence.
What did the original controlled trial establish?
The 2017 randomized trial enrolled 120 adults aged 60–80 for eight weeks. It tested NR plus pterostilbene and reported increased blood NAD. This supports a biochemical effect of the studied combination. It did not establish longer human lifespan or show that a specified percentage increase in blood NAD produces the same percentage improvement in energy.
How should the cholesterol findings be read?
That trial also reported LDL-cholesterol increases, more pronounced with the higher amount, while noting baseline group differences and uncertainty about interpretation. These findings should remain visible alongside the NAD result. They do not justify claiming every user will experience a cholesterol rise, or dismissing the finding as irrelevant. Someone monitoring cholesterol should bring the full formula and paper to the clinician managing that issue.
What about the 2026 menopause study?
A 2026 pilot followed 40 women for seven days; 32 reported menopause-transition symptoms and eight reported minimal or no symptoms. It was open-label, without a randomized placebo comparison. The authors reported symptom and hormone-ratio changes, but the design cannot reliably separate treatment effects from expectation or natural variation. Elysium employees were among the authors. This is preliminary research, not proof that Basis replaces established menopause care.
What do the quality links and price tell us?
The checked page displayed $65 per pouch and described a 30-day supply, with purchase and recurring-payment options. Confirm the selected plan and renewal terms in the cart. The manufacturer links lot documentation and a sports-certification lookup; check the actual lot rather than assuming every pouch is covered. Those documents address quality and testing scope, not proof of a particular health benefit.
Who should compare the details more closely?
Readers choosing between a simple NR capsule and an NR combination should consider what the added ingredient contributes, what uncertainty it introduces, and the full recurring cost. Compare Tru Niagen, NR, NMN, and NAD, and how to read a COA. For menopause-related claims, our women and men guide places the product marketing in a wider evidence context.
Sources & reading notes
Primary sources checked September 18, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Elysium: Basis Manufacturer label for NR plus pterostilbene; claims and lot documentation are separate evidence.
- Elysium: the science behind Basis Manufacturer describes the studied NR and pterostilbene combination; interpretation checked against the original paper.
- Dellinger et al. (2017): randomized NR plus pterostilbene trial Eight-week biomarker and safety study; lipid observations and baseline imbalance remain relevant.
- Holmes et al. (2026): open-label NRPT menopause pilot 40 women, seven days, no randomized placebo comparison; manufacturer employees among authors.
- FDA: questions and answers on dietary supplements Regulatory categories and limits of premarket review.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.